Literature DB >> 4014561

Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy.

J E Goodnight, W L Bargar, T Voegeli, F W Blaisdell.   

Abstract

Complete local control of 25 extremity bone and soft tissue sarcomas was obtained by combined preoperative intraarterial doxorubicin and radiation therapy, followed by limb-sparing resection with reconstruction and adjuvant chemotherapy. At a 32 month median follow-up, there are no local tumor recurrences. Functional limbs were salvaged in 21 patients (84 percent). Fifteen patients (60 percent) were continuously disease-free and overall survival was 80 percent. After the extensive combined modality therapy, extremity complications, including delays in wound healing, occurred in 10 patients. Nevertheless, most complications were resolved with salvage of functional limbs. These results support an aggressive multimodality limb-sparing approach to high-grade extremity sarcomas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4014561     DOI: 10.1016/0002-9610(85)90018-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

Review 1.  Preoperative therapy for extremity soft tissue sarcomas.

Authors:  Lara E Davis; Christopher W Ryan
Journal:  Curr Treat Options Oncol       Date:  2015-06

Review 2.  [Bone and soft tissue tumors--general strategy of therapy].

Authors:  H P Bruch
Journal:  Langenbecks Arch Chir       Date:  1987

3.  Vascularized tissue transfer for closure of irradiated wounds after soft tissue sarcoma resection.

Authors:  W J Barwick; J A Goldberg; S P Scully; J M Harrelson
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

4.  (Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series.

Authors:  Riikka Nevala; Erkki Tukiainen; Maija Tarkkanen; Tom Böhling; Carl Blomqvist; Mika Sampo
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.